SCHEMBL23329119

SCHEMBL23329119

O=C(NC1CCCCC1)c1nc(Cl)cc2cc[nH]c12

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.49
KMT2A Q03164 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.45
CNR1 P21554 1/20 0.45
CNR2 P34972 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
EPHX1 P07099 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CD38 P28907 3/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
MAPK14 Q16539 1/20 0.43
ALDH1A1 P00352 2/20 0.42
HTT P42858 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
LMNA P02545 1/20 0.42
TSHR P16473 1/20 0.42
DYRK1A Q13627 1/20 0.42
S1PR1 P21453 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30230488 0.81 CD38 (0.67) CD38
SCHEMBL23329118 0.81 CD38 (0.67) CD38
SCHEMBL22733237 0.80 CD38 (0.35) CD38
SCHEMBL22933148 0.80 CD38 (0.51) CD38
SCHEMBL23329201 0.75 GAA (0.65) GAAKMT2ACNR2SMN1; SMN2NPC1
SCHEMBL20612910 0.73 NPC1 (0.51) GAAKMT2AL3MBTL1CNR2EPHX1
SCHEMBL20612933 0.73 NPC1 (0.52) GAAKMT2AL3MBTL1CNR2SMN1; SMN2
SCHEMBL3276454 0.73 KEAP1 (0.42) ALDH1A1
SCHEMBL29691353 0.73 KEAP1 (0.42) ALDH1A1
SCHEMBL16506119 0.72 KDM4E (0.41) L3MBTL1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021087087-A1 N-CYCLOHEXYL-5-(THIAZOL-5-YL)-1H-INDOLE-7-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS CD38 INHIBITORS FOR INCREASING NAD+ AND FOR THE TREATMENT OF E.G. MUSCULAR DISORDERS MITOBRIDGE INC. (US) 2021-05-06 WO disclosed